Mizuho lowered the firm’s price target on Abbott (ABT) to $135 from $140 and keeps a Neutral rating on the shares following the Q2 report. The firm cut estimates on the sales guidance revision. The share selloff may be overdone but a potential rebound may be gradual, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $142 from $147 at Wells Fargo
- Abbott upgraded to Buy from Hold at Jefferies
- Abbott Laboratories Reports Strong Q2 2025 Results
- Abbott’s Earnings Call: Strong Growth Amid Challenges
- Abbott Laboratories: Temporary Challenges Amid Strong Long-Term Growth Prospects Justify Buy Rating